跳至主要内容
临床试验/NCT03032055
NCT03032055招募中不适用

Validation of a Predictive Score of Acute Chest Syndrome

Soutien aux Actions contre les Maladies du Globule Rouge1 个研究点 分布在 1 个国家目标入组 800 人开始时间: 2016年1月1日最近更新:
适应症

试验速览

阶段
不适用
状态
招募中
发起方
入组人数
800
试验地点
1
主要终点
Primary Outcome Measure of Validation of a Predictive Score of Acute Chest Syndrome

研究概览

简要总结

Vaso-Occlusive Crisis (VOC), the most common manifestation of sickle cell disease (SCD), is the first cause of death, particularly when complicated by an acute chest syndrome (ACS).

The PRESEV score could help the physicians to better manage VOC and could be used for future therapeutic trials. This predictive score of secondary ACS has to be validated in a multicenter international study.

详细描述

International multicentre prospective observational study.

Prediction of an ACS within 15 days after admission by the PRESEV2 score at arrival.

Validation of a Predictive Score of Acute Chest Syndrome (Presev2) associates a categorical pain score of the spine /or pelvis and 3 biological parameters: Reticulocytes, Leucocytes and Hemoglobin.

ACS is defined by crepitant or bronchial breathing or the association of new radiologic infiltrate and chest pain

Inclusion criteria:

研究设计

研究类型
Observational
观察模型
Cohort
时间视角
Prospective

入排标准

年龄范围
2 Years 至 —(Child, Adult, Older Adult)
性别
All
接受健康志愿者

入选标准

  • Inclusion criteria:
  • Children (>2 years) and adults
  • Male and Female
  • Homozygous SCD patients
  • VOC admitted at the emergency unit (a severe VOC is defined as pain or tenderness affecting at least one part of the body (e.g. limbs, ribs, sternum, head (skull), spine and/or pelvis) that required hospitalization and opioids (level 3), and is not attributable to other causes.
  • Patient has health care insurance (in Europe)
  • Written consent given after being informed of the purpose, progress and potential risks
  • Exclusion criteria:
  • No inaugural Acute Chest Syndrome
  • Homeless patients
  • Deprived of their liberty by a court or administrative order or under guardianship
  • Unable to understand the purpose and conditions of carrying out the study, unable to give consent

排除标准

  • 未提供

结局指标

主要结局

Primary Outcome Measure of Validation of a Predictive Score of Acute Chest Syndrome

时间窗: 2 years

The primary outcome mesure is the occurrence of an ACS defined by crepitant or bronchial breathing or the association of new radiologic infiltrats and chest pain during the first 15 days of hospitalization for Vaso Occlusive Crisis

次要结局

  • Secondary Outcome Measures: Validation of a Predictive Score of Acute Chest Syndrome(2 years)

研究者

发起方
Soutien aux Actions contre les Maladies du Globule Rouge
申办方类型
Other
责任方
Sponsor

研究点 (1)

Loading locations...

相似试验